These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 9027607)

  • 1. Identification of a chemoprevention cohort from a population of women at high risk for breast cancer.
    Fabian CJ; Kamel S; Zalles C; Kimler BF
    J Cell Biochem Suppl; 1996; 25():112-22. PubMed ID: 9027607
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Breast cytology and biomarkers obtained by random fine needle aspiration: use in risk assessment and early chemoprevention trials.
    Fabian CJ; Zalles C; Kamel S; Zeiger S; Simon C; Kimler BF
    J Cell Biochem Suppl; 1997; 28-29():101-10. PubMed ID: 9589354
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Breast cancer chemoprevention trials using the fine-needle aspiration model.
    Kimler BF; Fabian CJ; Wallace DD
    J Cell Biochem Suppl; 2000; 34():7-12. PubMed ID: 10762008
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mammographic density does not correlate with Ki-67 expression or cytomorphology in benign breast cells obtained by random periareolar fine needle aspiration from women at high risk for breast cancer.
    Khan QJ; Kimler BF; O'Dea AP; Zalles CM; Sharma P; Fabian CJ
    Breast Cancer Res; 2007; 9(3):R35. PubMed ID: 17537236
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multivariate analysis of DNA ploidy, p53, c-erbB-2 proteins, EGFR, and steroid hormone receptors for prediction of poor short term prognosis in breast cancer.
    Eissa S; Khalifa A; el-Gharib A; Salah N; Mohamed MK
    Anticancer Res; 1997; 17(2B):1417-23. PubMed ID: 9137508
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunohistochemical detection of EGFR, p185(erbB-2), Bcl-2 and p53 in breast carcinomas in pre-menopausal and post-menopausal women.
    Talley L; Chhieng DC; Bell WC; Grizzle WE; Frost AR
    Biotech Histochem; 2008 Feb; 83(1):5-14. PubMed ID: 18568671
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cancer risk factors for selecting cohorts for large-scale chemoprevention trials.
    Greenwald P
    J Cell Biochem Suppl; 1996; 25():29-36. PubMed ID: 9027595
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Carcinoma in situ of the female breast. A clinico-pathological, immunohistological, and DNA ploidy study.
    Ottesen GL
    APMIS Suppl; 2003; (108):1-67. PubMed ID: 12874968
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biomarkers for breast cancer.
    Beenken SW; Bland KI
    Minerva Chir; 2002 Aug; 57(4):437-48. PubMed ID: 12145573
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance.
    Arpino G; Weiss H; Lee AV; Schiff R; De Placido S; Osborne CK; Elledge RM
    J Natl Cancer Inst; 2005 Sep; 97(17):1254-61. PubMed ID: 16145046
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Estrogen receptor expression in benign breast ductal cells obtained from random periareolar fine needle aspiration correlates with menopausal status and cytomorphology index score.
    Sharma P; Kimler BF; Warner C; Metheny T; Xue Q; Zalles CM; Fabian CJ
    Breast Cancer Res Treat; 2006 Nov; 100(1):71-6. PubMed ID: 16791479
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical, histopathologic, and immunohistochemical features of microglandular adenosis and transition into in situ and invasive carcinoma.
    Khalifeh IM; Albarracin C; Diaz LK; Symmans FW; Edgerton ME; Hwang RF; Sneige N
    Am J Surg Pathol; 2008 Apr; 32(4):544-52. PubMed ID: 18300793
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlations among p53, Her-2/neu, and ras overexpression and aneuploidy by multiparameter flow cytometry in human breast cancer: evidence for a common phenotypic evolutionary pattern in infiltrating ductal carcinomas.
    Smith CA; Pollice AA; Gu LP; Brown KA; Singh SG; Janocko LE; Johnson R; Julian T; Hyams D; Wolmark N; Sweeney L; Silverman JF; Shackney SE
    Clin Cancer Res; 2000 Jan; 6(1):112-26. PubMed ID: 10656439
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Estrogen receptor-negative and human epidermal growth factor receptor 2-negative breast cancer tissue have the highest Ki-67 labeling index and EGFR expression: gene amplification does not contribute to EGFR expression.
    Umemura S; Takekoshi S; Suzuki Y; Saitoh Y; Tokuda Y; Osamura RY
    Oncol Rep; 2005 Aug; 14(2):337-43. PubMed ID: 16012712
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biomarker and cytologic abnormalities in women at high and low risk for breast cancer.
    Fabian CJ; Zalles C; Kamel S; McKittrick R; Moore WP; Zeiger S; Simon C; Kimler B; Cramer A; Garcia F
    J Cell Biochem Suppl; 1993; 17G():153-60. PubMed ID: 7911861
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multivariate analysis of DNA ploidy, p53, c-erbB-2 proteins, EGFR, and steroid hormone receptors for short-term prognosis in breast cancer.
    Eissa S; Khalifa A; el-Gharib A; Salah N; Mohamed MK
    Anticancer Res; 1997; 17(4B):3091-7. PubMed ID: 9329609
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ki-67 expression in benign breast ductal cells obtained by random periareolar fine needle aspiration.
    Khan QJ; Kimler BF; Clark J; Metheny T; Zalles CM; Fabian CJ
    Cancer Epidemiol Biomarkers Prev; 2005 Apr; 14(4):786-9. PubMed ID: 15824144
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Single cell multiple biomarker analysis in archival breast fine-needle aspiration specimens: quantitative fluorescence image analysis of DNA content, p53, and G-actin as breast cancer biomarkers.
    Rao JY; Apple SK; Hemstreet GP; Jin Y; Nieberg RK
    Cancer Epidemiol Biomarkers Prev; 1998 Nov; 7(11):1027-33. PubMed ID: 9829712
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A pilot study to establish a clinical model to perform phase II studies of breast cancer chemopreventive agents in women at high risk with biomarkers as surrogate endpoints for activity.
    Stearns V; Gallagher A; Kleer CG; Singh B; Freedman M; Haddad BR; Isaacs C; Warren R; Brown M; Cullen J; Trock B; Hayes DF
    Clin Cancer Res; 2004 Dec; 10(24):8332-40. PubMed ID: 15623610
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Morphologic and immunophenotypic markers as surrogate endpoints of tamoxifen effect for prevention of breast cancer.
    Mohsin SK; Allred DC; Osborne CK; Cruz A; Otto P; Chew H; Clark GM; Elledge RM
    Breast Cancer Res Treat; 2005 Dec; 94(3):205-11. PubMed ID: 16267611
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.